Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Key facts

Sponsor

SCRI Development Innovations, LLC

Principal Investigator

John D. Hainsworth, MD

SCRI Development Innovations, LLC

Intervention

paclitaxel(drug)

Enrollment

60 enrolled

Eligibility

18 years · All sexes

Timeline

2006 – 2009

Study locations (9)

• Integrated Community Oncology Network, Jacksonville, Florida, United States
• Northeast Georgia Medical Center, Gainesville, Georgia, United States
• Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
• Graves-Gilbert Clinic, Bowling Green, Kentucky, United States
• Baton Rouge General Medical Center, Baton Rouge, Louisiana, United States
• Oncology Hematology Care, Cincinnati, Ohio, United States
• Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
• Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
• Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cancer of unknown primary site

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07524114
  Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
  University Health Network, Toronto
• RECRUITINGNANCT07283939
  Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
  Alliance for Clinical Trials in Oncology
• RECRUITINGPHASE2NCT06995508
  Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
  Roswell Park Cancer Institute
• RECRUITINGPHASE1NCT06868433
  TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
  Emory University
• RECRUITINGPHASE3NCT06589804
  Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
  National Cancer Institute (NCI)
• RECRUITINGNANCT06662058
  Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
  Emory University
• RECRUITINGPHASE2NCT06636734
  Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
  Emory University
• RECRUITINGNANCT06644716
  [18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary Origin
  Erasmus Medical Center

See all trials for Cancer of unknown primary site →